Subtopic Deep Dive
Microtubule-Targeting Agents in Oncology
Research Guide
What is Microtubule-Targeting Agents in Oncology?
Microtubule-targeting agents (MTAs) are chemotherapeutic drugs that stabilize or destabilize microtubules to disrupt mitotic spindle function and inhibit cancer cell proliferation in oncology.
MTAs include stabilizers like taxanes (paclitaxel) and epothilones, and destabilizers like vinca alkaloids. These agents treat breast, lung, and sarcoma cancers by impairing microtubule dynamics during mitosis and interphase (Field et al., 2014, 246 citations; Zhou & Giannakakou, 2005, 463 citations). Over 20 papers from 2005-2020 detail their mechanisms, with Mukhtar et al. (2014, 541 citations) highlighting natural agents.
Why It Matters
MTAs form the backbone of metastatic cancer therapy, treating over one million patients with paclitaxel alone (Gallego-Jara et al., 2020, 308 citations). They address resistance via combination strategies, as explored in Fojo & Menefee (2007, 221 citations) on multidrug resistance. Risinger et al. (2008, 248 citations) emphasize their role in oncology by targeting microtubule dynamics, reducing tumor growth in clinical settings despite neurotoxicity challenges (Zhang et al., 2012, 396 citations).
Key Research Challenges
Drug Resistance Mechanisms
Cancer cells develop multidrug resistance to MTAs through microtubule-stabilizing agent alterations (Fojo & Menefee, 2007, 221 citations). This reduces efficacy in recurrent tumors. Zhou & Giannakakou (2005, 463 citations) detail evolving resistance pathways.
Neurotoxicity and Side Effects
MTAs like epothilone D cause axonal dysfunction and cognitive deficits (Zhang et al., 2012, 396 citations). Balancing antitumor effects with toxicity remains critical. Komlódi-Pásztor et al. (2012, 229 citations) critique mitosis-specific targeting flaws.
Overcoming Mitotic Targeting Limits
Purely mitotic inhibitors fail clinically due to interphase impairments being key to success (Field et al., 2014, 246 citations). Rationales for spindle protein inhibitors prove flawed (Komlódi-Pásztor et al., 2012, 229 citations). New stabilizers require distinct mechanisms (Kellogg et al., 2017, 230 citations).
Essential Papers
Targeting Microtubules by Natural Agents for Cancer Therapy
Eiman Mukhtar, Vaqar M. Adhami, Hasan Mukhtar · 2014 · Molecular Cancer Therapeutics · 541 citations
Abstract Natural compounds that target microtubules and disrupt the normal function of the mitotic spindle have proven to be one of the best classes of cancer chemotherapeutic drugs available in cl...
Targeting Microtubules for Cancer Chemotherapy
Jun Zhou, Paraskevi Giannakakou · 2005 · Current Medicinal Chemistry - Anti-Cancer Agents · 463 citations
Chemical compounds that interfere with microtubules such as the vinca alkaloids and taxanes are important chemotherapeutic agents for the treatment of cancer. As our knowledge of microtubule-target...
The Microtubule-Stabilizing Agent, Epothilone D, Reduces Axonal Dysfunction, Neurotoxicity, Cognitive Deficits, and Alzheimer-Like Pathology in an Interventional Study with Aged Tau Transgenic Mice
Bin Zhang, Jenna C. Carroll, John Q. Trojanowski et al. · 2012 · Journal of Neuroscience · 396 citations
Neurodegenerative tauopathies, such as Alzheimer's disease (AD), are characterized by insoluble deposits of hyperphosphorylated tau protein within brain neurons. Increased phosphorylation and decre...
Vinca alkaloids and analogues as anti-cancer agents: Looking back, peering ahead
Emanuela Martino, Giuseppe Casamassima, Sonia Angela Castiglione et al. · 2018 · Bioorganic & Medicinal Chemistry Letters · 328 citations
A Compressive Review about Taxol®: History and Future Challenges
Julia Gallego‐Jara, Gema Lozano Terol, Rosa Alba Sola Martínez et al. · 2020 · Molecules · 308 citations
Taxol®, which is also known as paclitaxel, is a chemotherapeutic agent widely used to treat different cancers. Since the discovery of its antitumoral activity, Taxol® has been used to treat over on...
Microtubule dynamics as a target in oncology
April L. Risinger, Francis J. Giles, Susan L. Mooberry · 2008 · Cancer Treatment Reviews · 248 citations
Microtubule-targeting agents are clinically successful due to both mitotic and interphase impairment of microtubule function
Jessica J. Field, Arun Kanakkanthara, John H. Miller · 2014 · Bioorganic & Medicinal Chemistry · 246 citations
Reading Guide
Foundational Papers
Start with Mukhtar et al. (2014, 541 citations) for natural MTA overview; Zhou & Giannakakou (2005, 463 citations) for mechanisms; Field et al. (2014, 246 citations) for mitotic/interphase roles.
Recent Advances
Gallego-Jara et al. (2020, 308 citations) on Taxol® challenges; Kellogg et al. (2017, 230 citations) on cryo-EM structures; Martino et al. (2018, 328 citations) on vinca analogues.
Core Methods
Microtubule stabilization/destabilization assays; cryo-EM for binding (Kellogg et al., 2017); dynamics analysis in oncology models (Risinger et al., 2008).
How PapersFlow Helps You Research Microtubule-Targeting Agents in Oncology
Discover & Search
Research Agent uses searchPapers and citationGraph to map MTA literature from Mukhtar et al. (2014, 541 citations), revealing clusters around taxanes and vinca alkaloids. exaSearch finds natural agents reviews, while findSimilarPapers expands to epothilones from Zhou & Giannakakou (2005).
Analyze & Verify
Analysis Agent applies readPaperContent to extract resistance mechanisms from Fojo & Menefee (2007), then verifyResponse with CoVe checks claims against 10+ papers. runPythonAnalysis plots microtubule dynamics data via matplotlib, with GRADE scoring efficacy evidence from Risinger et al. (2008).
Synthesize & Write
Synthesis Agent detects gaps in MTA combination therapies, flagging contradictions between mitotic vs. interphase actions (Field et al., 2014). Writing Agent uses latexEditText, latexSyncCitations for Mukhtar et al., and latexCompile to generate review manuscripts; exportMermaid diagrams stabilizer structures.
Use Cases
"Analyze survival data from taxane resistance studies in breast cancer MTA papers."
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas survival curves from Gallego-Jara et al., 2020) → matplotlib plots with GRADE-verified statistics.
"Draft LaTeX review on vinca alkaloids mechanisms with citations."
Research Agent → citationGraph (Martino et al., 2018) → Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations + latexCompile → formatted PDF.
"Find GitHub code for microtubule simulation models from MTA papers."
Research Agent → paperExtractUrls (Kellogg et al., 2017 cryo-EM) → Code Discovery → paperFindGithubRepo → githubRepoInspect → runnable dynamics simulation code.
Automated Workflows
Deep Research workflow scans 50+ MTA papers via searchPapers → citationGraph, producing structured reports on stabilizers vs. destabilizers with GRADE scores. DeepScan's 7-step chain analyzes resistance (Fojo & Menefee, 2007) with CoVe checkpoints and runPythonAnalysis. Theorizer generates hypotheses on natural MTA combinations from Mukhtar et al. (2014).
Frequently Asked Questions
What defines microtubule-targeting agents in oncology?
MTAs stabilize (taxanes, epothilones) or destabilize (vinca alkaloids) microtubules to disrupt mitosis and interphase, treating breast/lung cancers (Zhou & Giannakakou, 2005; Field et al., 2014).
What are key methods for MTAs?
Cryo-EM structures reveal taxane/non-taxane mechanisms (Kellogg et al., 2017, 230 citations); natural agents target spindles (Mukhtar et al., 2014, 541 citations).
What are foundational MTA papers?
Mukhtar et al. (2014, 541 citations) on natural agents; Zhou & Giannakakou (2005, 463 citations) on chemotherapy targeting; Risinger et al. (2008, 248 citations) on dynamics.
What open problems exist in MTA research?
Resistance via stabilization changes (Fojo & Menefee, 2007); neurotoxicity reduction (Zhang et al., 2012); interphase vs. mitotic efficacy (Komlódi-Pásztor et al., 2012).
Research Cancer Treatment and Pharmacology with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Microtubule-Targeting Agents in Oncology with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Cancer Treatment and Pharmacology Research Guide